Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harmony Biosciences excels in Q4, eyes growth in new markets

Harmony Biosciences delivered strong financial results, emphasizing growth strategies and confidence in WAKIX's revenue potential. The company is well-positioned with a focus on new prescribers, lifecycle management, and potential business development opportunities.

Harmony Biosciences excels in Q1, eyes expansion and shareholder value

Harmony Biosciences' Q1 2023 showcased strong financial performance, significant patient growth on WAKIX, and strategic plans for portfolio expansion.
The company's commercial model evolution and confidence in WAKIX's growth potential position it well for future opportunities.
Addressing challenges like patient attrition rates and regulatory concerns while exploring new business development avenues highlight Harmony's proactive approach.
With a focus on maximizing shareholder value and sustaining growth post-WAKIX, Harmony Biosciences remains poised for continued success.

Harmony Biosciences excels in Q2, eyes growth amid challenges

Harmony Biosciences delivered a strong Q2 performance, showcasing growth in net sales and patient numbers for WAKIX. The company's financial strength, strategic capital deployment, and focus on clinical development programs position it well for future growth. While facing challenges like patent disputes and market dynamics, Harmony Biosciences remains confident in its business fundamentals and growth potential.

Harmony Biosciences Achieves Record Revenue in Q3 2023

Harmony Biosciences delivered a stellar performance in Q3 2023, marked by record revenue, strong profitability, and strategic acquisitions, positioning the company for future growth.
While facing challenges in patent litigation and regulatory approvals, the company's focus on innovation, commercial excellence, and financial strength underpin its resilience.
With a clear market opportunity in narcolepsy, ongoing pipeline advancements, and a commitment to shareholder value, Harmony Biosciences remains well-positioned for long-term success.

Harmony Biosciences reports robust earnings, eyes strategic growth in 2024

Harmony Biosciences' strong financial performance, strategic acquisitions, and clinical advancements position the company for continued growth and market success.
Balancing revenue growth, pricing strategies, and clinical developments will be key focus areas for the company in navigating market challenges and opportunities.
With a focus on innovation, regulatory relationships, and financial prudence, Harmony Biosciences aims to drive sustainable growth and shareholder value in 2024.
The company's proactive approach to business development, share repurchases, and revenue guidance reflects a strategic and forward-thinking mindset for future success.

Harmony Biosciences excels in Q1, poised for long-term growth

Harmony Biosciences delivered strong financial performance in Q1, driven by WAKIX's growth and strategic acquisitions, positioning the company for continued success.
Despite operational challenges and market competition, the company's focus on innovation, rare disease treatments, and CNS franchises presents significant growth opportunities.
With a robust financial position, disciplined capital deployment, and a promising pipeline, Harmony Biosciences is poised for long-term value creation and revenue growth.
FDA recognition of unmet medical needs, positive clinical developments, and strong IP protection underscore the company's potential for market leadership and patient impact.

Harmony Biosciences reports robust Q2 performance and growth opportunities

Harmony Biosciences delivered a strong Q2 performance with revenue growth, FDA approvals, and pipeline advancements. The company's financial strength, upheld patents, and strategic growth focus position it well for future success despite some challenges.

Harmony Biosciences excels in Q3, eyes growth amid legal challenges

Harmony Biosciences demonstrated strong financial performance and pipeline progress in Q3 2024, positioning itself for continued growth.
While facing IP litigation and challenges in rare orphan categories, the company's focus on innovation and market positioning presents opportunities for future success.
Maintaining financial strength, pursuing pipeline advancements, and navigating legal hurdles will be key for Harmony Biosciences' sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will be providing a comprehensive pipeline update at its Investor Day event today, showcasing new data from its orexin-2 receptor agonist, next-generation pitolisant programs, and long-term extension data from its pitolisant program in idiopathic hypersomnia.

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

HRMY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Harmony Biosciences Holdings, Inc. investment

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?

PLYMOUTH MEETING, Pa. , Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m.

HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses.

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Harmony Biosciences (HRMY) Upgraded to Buy: Here's What You Should Know

Regeneron Pharmaceuticals

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders.

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?

HRMY or REGN: Which Is the Better Value Stock Right Now?

Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?

PLYMOUTH MEETING, Pa. , Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m.

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Harmony Biosciences' main product, WAKIX, drives significant revenue growth, with expansion potential in treating narcolepsy and other conditions, despite past controversies. The company's strategic acquisitions, including Zynerba and Epygenix, aim to diversify its portfolio, reducing reliance on WAKIX and boosting long-term growth prospects. Harmony's financial health is strong, with substantial cash reserves and high margins, allowing continued investment in research and development.

Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential

Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Harmony Biosciences (HRMY) Stock

Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential.

Harmony Biosciences: Advancing An Expanded Pipeline

The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Level Wall Street Analysts Expect?

Should Value Investors Buy Harmony Biosciences (HRMY) Stock?

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per share a year ago.

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia (IH) in Fourth Quarter 2024 Reiterates 2024 Net Product Revenue Guidance of $700 - $720 Million Company to Host Investor Day in New York City on October 1st Conference Call and Webcast to be Held Today at 8:30 a.m. ET  PLYMOUTH MEETING, Pa.

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

PLYMOUTH MEETING, Pa. , July 23, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, before the open of the U.S. financial markets.

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 32.8% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?

Alnylam Pharmaceuticals

Amgen

Exelixis

Gilead Sciences

Incyte

Bio-Techne

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.

News for Harmony Biosciences Holdings Stock (HRMY)